The Phase I trial of Neuralstem's spinal cord stem cells found one patient showed improvement in clinical status, while the treatment was safe and tolerable for all 12 patients. The trial has been approved to proceed with cervical transplantations targeting motor neurons that control respiratory function.
Nine patients with amyotrophic lateral sclerosis (ALS) were treated with Neuralstem's spinal cord stem cells, showing no unresolved serious adverse reactions or death. The trial indicates the feasibility of transplanting stem cells directly into the spinal cord, paving the way for future treatments.
The phase I safety trial of Neuralstem's human spinal cord stem cells in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology Annual Meeting, featuring interim safety data on nine patients. The trial is designed to evaluate the safety of the cells and surgery procedure for ALS treatment.
Neuralstem's spinal cord stem cells survive and differentiate into neurons in rat brains affected by stroke, leading to improved motor skill and strength measurements. The study shows significant promise for treating post-stroke symptoms and paralysis.